Recurrent Mycosis Fungoides Withdrawn Phase 1 Trials for Brentuximab vedotin (DB08870)

Also known as: Mycosis fungoides recurrent

IndicationStatusPhase
DBCOND0080283 (Recurrent Mycosis Fungoides)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03373305Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasTreatment